← All trials
NCT04516746
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2020
- Primary completion
- Mar 23, 2021
- Completion date
- Feb 21, 2023
- First posted
- Aug 18, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 40000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Columbia UniversityOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.